Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN is navigating 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 4 distinct examiners across 3 distinct art units. This distribution shows that the university's applications are being reviewed by multiple specialists in 3 different units. For a practitioner, this suggests that the university's research is technically diverse and triggers review by multiple specialized groups at the patent office.
DENT, ALANA HARRIS is the busiest examiner for the portfolio, with 1 pending office action under review. With 4 total pending office actions and multiple distinct examiners, the busiest examiner is responsible for 1 action. The use of 3 distinct art units for the actions suggests that the university's biotechnology research is spread across different specialized groups. This requires a prosecution strategy that manages the different examiners across the 3 units, each potentially having different examination priorities and technical standards.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DENT, ALANA HARRIS | 1 | 44.2% | +32.0% |
| LEAVITT, MORDECAI MIZANI | 1 | 100.0% | +0.0% |
| LUNDE, GRACE HENRY | 1 | 63.0% | +38.9% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18223333 | EMBEDDING OF CATALYTICALLY ACTIVE NANOPARTICLES INTO SUPERSTRUCTURES OF PLASMONIC NANOPARTICLES TO ENHANCE THE PHOTOCATALYTIC ACTIVITY | LEAVITT, MORDECAI MIZANI | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044628 | ENGINEERED AAV VECTORS | ALAM, DANYAL HASSAN | 1d overdue |
| 18321344 | CD28-TARGETING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, METHODS OF GENERATION AND USES THEREOF | LUNDE, GRACE HENRY | 77d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18321344 | CD28-TARGETING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, METHODS OF GENERATION AND USES THEREOF | LUNDE, GRACE HENRY | 77d |
| 18292001 | ANTI-CD47 ANTIBODIES AND USE THEREOF | DENT, ALANA HARRIS | — |
| Art Unit | Apps |
|---|---|
| 1742 | 1 |
| 1641 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18292001 | ANTI-CD47 ANTIBODIES AND USE THEREOF | DENT, ALANA HARRIS | — | §112 | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18223333 | EMBEDDING OF CATALYTICALLY ACTIVE NANOPARTICLES INTO SUPERSTRUCTURES OF PLASMONIC NANOPARTICLES TO ENHANCE THE PHOTOCATALYTIC ACTIVITY | LEAVITT, MORDECAI MIZANI | 1742 | §103Other | Non-Final OA | — | Pending | Jul 18, 2023 |
| 18321344 | CD28-TARGETING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, METHODS OF GENERATION AND USES THEREOF | LUNDE, GRACE HENRY | 1641 | §101§103§112 | Non-Final OA | 77d | Pending | May 22, 2023 |
| 18044628 | ENGINEERED AAV VECTORS | ALAM, DANYAL HASSAN | 1672 | §103§112 | Non-Final OA | 1d overdue | Pending | Mar 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial